Publications by authors named "S Seleri Assuncao"

Unlabelled: Clinical trial participation across disease areas, including Alzheimer's disease (AD), has been biased towards White participants of European ancestry. To support clinical decision-making across diverse populations, we must recognize and address barriers to trial participation. To inform the design of ALUMNI AD, a trial focused on historically underrepresented AD populations, we held advice-seeking fora with key stakeholders to understand barriers and identify potential solutions to maximize trial participation of underrepresented racial and ethnic groups in the US.

View Article and Find Full Text PDF

Heavy metals can play an important biological role as micronutrients but also as potentially toxic elements (PTEs). Understanding the natural concentrations of PTEs-Pb and Zn included-in soils allows for the identification and monitoring of contaminated areas and their role in environmental risk assessment. In this study, we aim to determine semi-total or natural and available concentrations of Pb and Zn in topsoils (0-20 cm depth) from 337 samples under native vegetation in the State of Minas Gerais, Brazil.

View Article and Find Full Text PDF

Introduction: An Alzheimer's disease (AD) dementia diagnosis is often preceded by an extended period of cognitive decline. Few studies have examined healthcare resource use (HRU) during an extended period before AD dementia diagnosis.

Methods: In a historical claims-based cohort study, propensity score-matched cohorts of patients with and without AD dementia were observed for a 5-year prediagnosis period and a 1-year postdiagnosis period.

View Article and Find Full Text PDF

Psoriasis is an inflammatory skin disease characterized by keratinocyte proliferation and inflammatory cell infiltration induced by IL-17. However, the molecular mechanism through which IL-17 signaling in keratinocytes triggers skin inflammation remains not fully understood. Pyruvate kinase M2 (PKM2), a glycolytic enzyme, has been shown to have non-metabolic functions.

View Article and Find Full Text PDF
Article Synopsis
  • This review discusses gantenerumab, a fully human anti-amyloid monoclonal antibody aimed at treating Alzheimer's disease (AD) by targeting and potentially reversing amyloid plaque pathology.
  • The development faced challenges, including failed molecules from drug-related issues and study design flaws, but gained momentum with the FDA's approval of aducanumab as a disease-modifying therapy.
  • The gantenerumab development includes lessons from past research, focusing on amyloid positivity for patient selection, ensuring a measurable clinical decline, and prioritizing a manageable subcutaneous delivery method.
View Article and Find Full Text PDF